Breaking News
Trump orders huge wave of missile strikes on Iran in major escalation as chilling warning...
Le Pen Would Beat Every Rival In 2027, Major French Poll Finds
Lavrov Says NATO Military Activity In Arctic Threatens Russia's Security
Judge To Rule Today On Whether Alleged Charlie Kirk Assassin Will Stand Trial
Top Tech News
Here's What to Expect as Air Taxis Actually Begin to Take Off
'Wood Foam' Startup Uses Logging Waste as Substitute for Plastic, Producing 400 Pounds Daily
How a Group of Young Men in 1933 Solved a Water Crisis in The Desert -- And Nobody Knows About It
This American Battery Could Break China's Grip On The EV Supply Chain
Tesla's Cybercab Launch Is Next Week. Here's What Tesla Still Needs To Prove
800-passenger commercial plane boldly reinvents how we will fly
Does Ultra-Fast Charging Ruin An EV Battery? BYD Did It 350 Times In 9 Days To Find Out
Singapore is experimenting with biological computing using living human neurons...
It's Happening - Europe is Building an Impossible Fusion Reactor
Portable 1MW Kaleidos Microreactor Secures Critical Nuclear Fuel Deal Through 2030s
Gene therapy for color blindness passes first phase of human testing
Total color blindness, or achromatopsia, is generally an inherited disease caused by mutations in one of six different genes, with the majority of cases involving variants in either the CNGA3 or CNGB3 genes. The new gene therapy being trialed focuses on correcting a defect in the CNGA3 gene.
The treatment is somewhat similar to one of the first FDA-approved gene therapies, for vision loss, called Luxturna. These treatments attach a healthy functioning gene to a genetically modified harmless virus. The treatment is injected into a patient's eye and hopefully the correctly functioning gene begins producing whatever protein was previously missing, helping cure the condition caused by the defective gene.